33 Hematopoetic Stem Cell Transplant 1 1 0 7 7 105 http://clinicaltrials.dfhcc.harvard.edu/trials/105 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's quality of life. PURPOSE: This randomized phase III trial is studying a Web-based stem cell transplant support system to see how well it works compared with standard care in families of young patients undergoing a stem cell transplant. Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant Phase 3 143 http://clinicaltrials.dfhcc.harvard.edu/trials/143 Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors The purpose of the study is to: - Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors - Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis - Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients - Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant Phase 3 150 http://clinicaltrials.dfhcc.harvard.edu/trials/150 Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) This trial is designed to evaluate the feasibility, safety and efficacy of most closely HLA-matched multivirus specific CTL lines (CHM-CTLs) in HSCT patients with EBV, CMV or adenovirus infections that are persistent despite standard therapy. Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant Phase 1 272 http://clinicaltrials.dfhcc.harvard.edu/trials/272 Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Following an Allogeneic Stem Cell Transplant This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation. The impact of the conditioning regimen on the presence of the circulating regulatory as compared to activated T cell populations will be assessed.The recovery of DC populations post-transplant will be examined, along with the effect of the regimen on disease free and overall survival. Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant Phase 1 126 http://clinicaltrials.dfhcc.harvard.edu/trials/126 Iron Overload in Stem Cell Transplant Recipients The goal of this study is to examine the impact of iron overload in patients undergoing a bone marrow transplant. We believe that the iron status in these patients is associated with complications for transplant survivors. We will examine the iron status in these patients by MRI and by screening for mutations in genes known to cause iron overload. We will also determine the levels of hepcidin (a hormone produced in the liver that appears to regulate iron homeostasis) from blood and urine. Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant N/A 1272 http://clinicaltrials.dfhcc.harvard.edu/trials/1272 Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients. Recruiting 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant 1421 http://clinicaltrials.dfhcc.harvard.edu/trials/1421 Evaluating the Safety and Effectiveness of Stem Cell Transplants From Unrelated Donors in Children With Sickle Cell Disease (BMT CTN #0601) (The SCURT Study) Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant is a treatment option for someone with a severe form of the disease. Prior to undergoing a transplant, people typically receive a conditioning regimen of high doses of chemotherapy and other medications to prepare the body to accept the transplant. A conditioning regimen that uses lower doses of chemotherapy and medications may be safer for transplant recipients. This study will evaluate the safety and effectiveness of blood stem cell transplants, using either bone marrow or umbilical cord blood from unrelated donors, in children with severe SCD who receive a reduced intensity conditioning regimen prior to the transplant. Recruiting 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 33 Hematopoetic Stem Cell Transplant http://clinicaltrials.dfhcc.harvard.edu/diagnoses/33-hematopoetic-stem-cell-transplant